Lars Henrik Fugger

HLA variation and disease

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperReviewResearchpeer-review

DOI

  • Calliope A Dendrou, Nuffield Department of Medicine, The Wellcome Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK.
  • ,
  • Jan Petersen
  • Jamie Rossjohn, Division of Infection and Immunity, Cardiff University School of Medicine, Heath Park, Cardiff CF14 4XN, UK.
  • ,
  • Lars Fugger

Fifty years since the first description of an association between HLA and human disease, HLA molecules have proven to be central to physiology, protective immunity and deleterious, disease-causing autoimmune reactivity. Technological advances have enabled pivotal progress in the determination of the molecular mechanisms that underpin the association between HLA genetics and functional outcome. Here, we review our current understanding of HLA molecules as the fundamental platform for immune surveillance and responsiveness in health and disease. We evaluate the scope for personalized antigen-specific disease prevention, whereby harnessing HLA-ligand interactions for clinical benefit is becoming a realistic prospect.

Original languageEnglish
JournalNature Reviews. Immunology
Volume18
Issue5
Pages (from-to)325-339
Number of pages15
ISSN1474-1733
DOIs
Publication statusPublished - May 2018

See relations at Aarhus University Citationformats

ID: 130855615